• ABOUT
  • TEAM
  • SERVICES
  • RESULTS
  • NEWS
  • CAREERS

Plexus Ventures Assists Elthera AG in the Licensing of its First-in-Class Antibody

by plexusventures_h3tnl0 | Feb 17, 2023 | Uncategorized

Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce the successful completion of an out-licensing project conducted on behalf of its client, Elthera AG of Switzerland.  Plexus Ventures served as the exclusive business development advisor  to Elthera in...

Celon Pharma enters agreement with Zydus Lifesciences Ltd.

by plexusventures_h3tnl0 | Dec 2, 2022 | Uncategorized

Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce the successful conclusion of a licensing agreement of behalf of our client, Celon Pharma. Mr. Michael O’Sullivan, Plexus Ventures’ Managing Partner, stated: “This transaction is an ideal match which...

Mindpax engages Plexus Ventures as Exclusive Advisor to Partner its Digital Platform for Severe Mental Illnesses

by plexusventures_h3tnl0 | Oct 18, 2022 | No About

Philadelphia and Prague –  Mindpax, the innovative digital therapeutics company focused on improving the lives of people with Severe Mental Illnesses (SMIs), has engaged Plexus Ventures as its contract business development organization to identify partners for further...

Plexus Ventures’ Important Company Announcement

by plexusventures_h3tnl0 | Jun 7, 2022 | Uncategorized

Philadelphia, Pennsylvania – Plexus Ventures, a prominent corporate and business development boutique for healthcare companies, is pleased to announce our newest Managing Director. The Partners at Plexus Ventures are very pleased to announce that Ahmed Al-Derzi has...
« Older Entries

Recent Posts

  • Plexus Ventures Assists Elthera AG in the Licensing of its First-in-Class Antibody
  • Celon Pharma enters agreement with Zydus Lifesciences Ltd.
  • Mindpax engages Plexus Ventures as Exclusive Advisor to Partner its Digital Platform for Severe Mental Illnesses
  • Plexus Ventures’ Important Company Announcement
  • Plexus Ventures Assists Valeas S.p.A. to acquire from Pharmactive Biotech Products, SL, Spain licensing and distribution rights for its premium Affron®-based product for commercialization in Italy

Recent Comments

    Collaborating with clients to grow their businesses; committing our experience, resources and time to their success.

    Business Builders in Healthcare

    Contact Us
    • Follow
    • Follow

    About Us

    Our Team

    Areas of Expertise

    Project Portfolio

    What’s Trending

    Join Plexus